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present study was to determine whether a chronic treatment 
with a NO synthase inhibitor, L-NAME (Nω- nitro-L-arginine 
methyl ester) accelerates the renal dysfunction in younger adult 
spontaneously hypertensive rats (SHR). Indeed, in this model, the 
alterations in cardiac function mimic those observed in aging SHR. 
Male SHR were subjected to chronic L-NAME-treatment (6 mg/
kg/day) for two weeks. At 19 weeks, the kidneys were isolated, 
perfused with oxygenated physiological salt solution and changes 
in renal perfusion pressure continuously recorded. During a 
sustained constriction caused by methoxamine, bolus injections 
of acetylcholine and of the NO donor sodium nitroprusside caused 
dose-dependent dilatations in both groups of SHR. The responses 
to acetylcholine were not affected by the L-NAME treatment while 
those to sodium nitroprusside were signi cantly augmented. In 
the two groups, indomethacin, a cyclooxygenase inhibitor, did 
not affect the vasodilatation caused by acetylcholine. However, 
an acute treatment with another NO synthase inhibitor, L-nitro-
arginine, produced a major inhibition of the acetylcholine 
response in the SHR while it did not affect it in the kidney of SHR 
chronically treated with L-NAME. In the presence of indomethacin 
plus L-nitro-arginine, TRAM-34, an inhibitor of Ca2+-activated 
K+ channels of intermediate conductance, IK(Ca), blocked the 
responses to acetylcholine in both groups of SHR. These data show 
that in SHR, the acetylcholine-induced vasodilatation involves 
both NO release and an endothelium-derived hyperpolarizing 
factor (EDHF)-mediated component while in the L-NAME-treated 
SHR, the NO-component is abolished and the EDHF-mediated 
component becomes the major contributor to this vasodilatation. 
In the kidney of L-NAME-treated SHR, EDHF-mediated responses are 
a compensatory mechanism that sustain endothelium-dependent 
dilatations when NO activity is impaired. The responses involve 
IK(Ca), activation and must be further characterized.
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Our aim was to better understand the changes in expression in 
vascular smooth muscle cells during ageing using non pathological 
human mammary artery. We de ned 2 groups of patients: a group 
of young ones, Y, composed of men under 60 years old (43 to 60, 
13 patients) and a group of old ones, O, composed of men over 75 
years old (75 to 83, 11 patients). After dissection of the artery, 
medias were crushed and total RNA including microRNAs were 
collected.
Using microRNA array, we found that 90 microRNAs are expressed in 
the media from these patients. After statistical analysis no change 
in microRNA expression was found between the O and the Y groups. 
Therewere a lot of heterogeneity between the patients inside each 
group. It seems that vascular aging do not affect miRNA expression 
in our study, but the two groups of age were maybe too close to 
see some regulation.
Using DNA microarray, we found 233 genes signi catively regulated 
between the O group and the Y group. Among them, 60 genes were 
modulated more than 1.4 fold. We choose to verify these expression 
changes for 20 of them (the most regulated, newly identi ed or 
implicated in ageing) by quantitative RT-PCR and con rmed the 
regulation for 14 genes: compared to the Y, in the O group we 
saw an overexpression (from 1.4 to 8 fold) for 9 genes and an 
inhibition (from -1.5 to -3.2 fold) for 5 other genes. We focused on 
overexpressed Osteopontin, WISP1 (Wnt inducible secreted protein 
1), Gamma S Crystallin (for instance only described in lens and 
which could be a chaperon) and on inhibited Cystathionase (which 
produces H2S, an artery vasodilatator). The changes observed in 
mRNA expression were also seen in protein expression by Western 
Blot although less clearly due to strong inter-individual variability.
We also found that Wnt/beta-catenin signalization pathway was 
more activated in the O group. We notably found that beta-catenin 
phosphorylation on Ser 552 and Ser 675, which leads to beta-
catenin transfer in the nucleus, was increased.
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Le remodelage cardiaque au cours du vieillissement est caractérisé 
par une réduction massive du nombre de cardiomyocytes qui 
participe aux dysfonctionnements cardiaques observés chez le 
sujet âgé. Cette perte de cardiomyocytes par nécrose ou apoptose 
s’accompagne d’une part de l’hypertrophie compensatrice des 
cardiomyocytes restants, et d’autre part du dépôt de matrice 
extracellulaire conduisant à la  brose et la rigidi cation du 
myocarde. Le stress oxydant est un élément déterminant du 
remodelage cardiaque chez les individus âgés. Nous avons 
montré que la Monoamine oxydase-A (MAO-A) est une source de 
stress oxydant dans le cœur et que son expression est fortement 
augmentée dans le cœur âgé. De plus, la production d’H202 par la 
MAO-A lors la dégradation de sérotonine, induit l’apoptose et la 
nécrose des cardiomyocytes in vitro. De ce fait, l’augmentation de 
l’activité de la MAO-A au cours du vieillissement pourrait conduire 
au remodelage et à l’insuf sance cardiaque via l’accumulation 
d’H202.
A n de modéliser l’augmentation de l’expression de la MAO-A 
au cours du vieillissement, nous avons établi des lignées de 
souris transgéniques surexprimant la MAO-A sous le contrôle du 
promoteur α-MHC. Deux lignées dénommées 61 et 113 ont été 
obtenues, qui présentent une surexpression cardiaque spéci que 
de la MAO-A de 9142 et 38526 pmol/min/mg de protéines 
respectivement par rapport aux souris non transgéniques (31 
pmol/min/mg prot) ainsi qu’un taux basal de H202 mitochondrial 
accru. De manière intéressante, ces deux lignées présentent une 
mortalité précoce, corrélée avec l’activité de la MAO-A dans le 
coeur. La caractérisation fonctionnelle par échocardiographie 
montre une baisse importante des performances cardiaques et 
une dilatation du ventricule gauche, caractéristiques des stades 
